佰仁医疗(688198) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was RMB 76,265,199.91, representing a year-on-year increase of 17.53%[11] - The net profit attributable to shareholders for Q1 2024 was RMB 8,319,805.58, showing a decline of 28.88% compared to the same period last year[11] - Basic earnings per share for Q1 2024 were RMB 0.06, down 33.33% compared to the same period last year[11] - The net profit after deducting non-recurring gains and losses was RMB 6,377,822.50, a decrease of 29.26% year-on-year[11] - The total comprehensive income for Q1 2024 was CNY 5,288,083.31, down from CNY 11,461,029.65 in Q1 2023, reflecting a decline of 53.8%[47] - The company's total profit for Q1 2024 was $4.81 million, down from $14.13 million in Q1 2023, a decrease of about 66.0%[53] Research and Development - Research and development expenses totaled RMB 40,109,397.09, an increase of 130.45% year-on-year, accounting for 52.59% of operating revenue, up 25.77 percentage points[5][11] - R&D expenses for the period reached CNY 39.21 million, a significant increase of 151.90% year-over-year, accounting for 51.42% of total revenue[26] - The increase in R&D spending was primarily due to rising clinical trial costs, employee compensation, and depreciation expenses[28] - The company is focusing on strengthening its basic research and product development investments, with ongoing progress in key products[26] Cash Flow and Assets - The net cash flow from operating activities was negative at RMB -9,996,863.18, a decline of 151.22% year-on-year[11] - The cash flow from investing activities showed a net outflow of CNY 24,368,707.16 in Q1 2024, compared to a net outflow of CNY 48,247,368.69 in Q1 2023, indicating an improvement[48] - The cash and cash equivalents at the end of Q1 2024 were CNY 259,104,030.78, compared to CNY 98,617,977.18 at the end of Q1 2023, showing a significant increase[48] - Total cash inflow from operating activities amounted to $85.95 million in Q1 2024, compared to $77.96 million in Q1 2023, an increase of about 10.5%[59] - Total cash outflow from operating activities rose to $95.94 million in Q1 2024, up from $58.45 million in Q1 2023, reflecting an increase of approximately 64.1%[59] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 2,680[7] - The company's equity attributable to shareholders was CNY 1.21 billion as of March 31, 2024, compared to CNY 1.19 billion at the end of 2023[43] Liabilities and Assets - Total assets at the end of the reporting period were RMB 1,309,227,467.41, a decrease of 1.34% from the end of the previous year[5] - The company reported a total of CNY 605.15 million in current assets as of March 31, 2024, down from CNY 679.22 million at the end of 2023[39] - The total liabilities amounted to CNY 112.59 million, a decrease from CNY 138.47 million in the previous period[43] - The company reported a decrease in accounts payable from CNY 51,523,172.79 in Q1 2023 to CNY 34,797,874.38 in Q1 2024, a reduction of 32.4%[51] - The company’s deferred tax assets decreased from CNY 24,162,416.13 in Q1 2023 to CNY 22,689,690.59 in Q1 2024, a decline of 6.1%[51] - The company’s other non-current assets increased from CNY 234,652,986.01 in Q1 2023 to CNY 278,724,634.43 in Q1 2024, an increase of 18.7%[51] Operational Matters - The company has not reported any significant mergers or acquisitions during the reporting period[34] - There are no other significant operational matters that need to be brought to investors' attention for the reporting period[37]